Statistical analysis of p16Ink4a protein expression in reference to clinical data in the CaexPA group
| p16Ink4a expression in CaexPA | Positive | Borderline | No expression | Statistic | P value* |
| Age, years (mean 55.32) | 52.61 | 58.75 | 53.75 | H (2, N=47)=3.27 | 0.1946c |
| Gender | |||||
| Men (n=25) | 11 (44%) | 12 (48%) | 2 (8%) | χ2(2)=0.65 | 0.72085b |
| Women (n=22) | 12 (54.5%) | 8 (36.4%) | 2 (9.1%) | ||
| Tumour size, mm (mean 44.11) | 43.39 | 46.25 | 37.5 | H (2, N=47)=1.40 | 0.4956c |
| Duration of symptoms, months (mean=110.57) | 95.87 | 119.60 | 150.0 | H (2, N=47)=0.20 | 0.9064c |
| Type of symptoms | |||||
| Malignant (n=24) | 13 (54.2%) | 8 (33.3%) | 3 (12.5%) | χ2(2)=2.17 | 0.33773b |
| Benign (n=23) | 10 (34.4%) | 12 (52.2%) | 1 (4.4%) | ||
| Recurrence | |||||
| No (n=31) | 17 (54.8%) | 11 (35.5%) | 3 (9.7%) | χ2(2)=1.22 | 0.54355b |
| Yes (n=15) | 6 (40%) | 8 (53.3%) | 1 (6.7%) | ||
| Distant metastases | |||||
| No (n=20) | 11 (55.0%) | 7 (35.0%) | 2 (10.0%) | χ2(2)=1.71 | 0.17930b |
| Yes (n=20) | 8 (38.1%) | 12 (57.1%) | 0 (0.0%) |
*(b—χ2 test, c—Kruskal-Wallis test).
CaexPA, carcinoma ex pleomorphic adenoma.